TD Cowen analyst Marc Frahm initiates coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating.The analyst comments "DMRA is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE